Science-Backed Health
Countless conditions have been linked to a microbiome imbalance, and restoring the microbiome has shown success in treating the underlying conditions, not just the symptoms. The science speaks for itself.
Cardiometabolic & Vascular Conditions
Type 2 diabetes
Strengthened barrier integrity and SCFA-mediated incretin signaling (e.g., GLP-1) improve post-meal glucose control and insulin action.
Read the study here
Obesity
A balanced microbiome raises satiety signals (GLP-1/PYY), lowers endotoxin-driven inflammation, and optimizes bile-acid/FXR–TGR5 pathways, helping reduce overeating and adiposity.
Read the study here
Hypertension
Microbial SCFAs act on vascular and renal receptors (GPR41/43) to support endothelial function, nitric-oxide biology, and healthier blood-pressure regulation.
Read the study here
Atherosclerotic CVD
Microbiome balance reduces pro-atherogenic metabolites (e.g., TMAO) and systemic inflammation, supporting plaque stability and vascular health.
Read the study here
MASLD (formerly NAFLD)
Reduced gut permeability and reshaped bile-acid pools decrease hepatic fat signaling and inflammatory traffic to the liver.
Read the study here
Neurodegenerative Diseases
Alzheimer’s disease
SCFAs and indole metabolites from a healthy microbiome calm microglial activation and reduce neuroinflammatory signaling along the gut–brain axis.
Read the study here
Parkinson’s disease
Restored barrier function and SCFA output reduce enteric inflammation and aberrant α-synuclein–triggering cues that propagate to the brain.
Read the study here
Gastrointestinal Inflammatory & Functional Conditions
IBD (Crohn’s/UC)
Restoring butyrate producers and mucus-layer integrity cools mucosal immune activation and supports remission stability.
Read the study here
IBS
Balanced fermentation profiles and barrier repair reduce visceral hypersensitivity, gas, and stool irregularity.
Read the study here
SIBO
Microbiome normalization re-establishes small-bowel colonization resistance and motility cues, reducing fermentative bloating and pain.
Read the study here
GERD
Healthier upper-GI/intestinal ecosystems improve motility and barrier interactions that drive reflux-related inflammation.
Read the study here
Autoimmune & Inflammatory (Systemic) Conditions
Rheumatoid arthritis
A tolerant, butyrate-rich microbiome reduces pathobiont expansion (e.g., Prevotella spp.) and promotes Treg activity that eases joint-directed autoimmunity.
Read the study here
Systemic lupus erythematosus
Normalized communities limit blooms like Ruminococcus gnavus, reducing molecular mimicry, permeability, and flare-related inflammation.
Read the study here
Multiple Sclerosis
Microbial metabolites and dysbiosis associate with elevated blood pressure. Restoration of microbiome treats this.
Read the study here
Ankylosing spondylitis/spondyloarthritis
Rebalancing intestinal taxa reduces gut–joint inflammatory cross-talk and Th17 activation central to disease activity.
Read the study here
Dermatologic (Gut–Skin Axis)
Acne vulgaris
Reduced endotoxin and insulin/IGF-1–linked signals from a balanced microbiome dampen sebaceous inflammation.
Read the study here
Atopic dermatitis
Butyrate-driven Treg expansion and improved barrier integrity reduce the itch–inflammation loop.
Read the study here
Psoriasis
Microbiome rebalance lowers Th17-driving metabolites and permeability that fuel systemic skin inflammation.
Read the study here
Rosacea
Correcting dysbiosis—including SIBO-related patterns—reduces neurovascular triggers behind flushing and papules.
Read the study here
Women's Health
PCOS
Butyrate and bile-acid signaling from a healthy microbiome improve insulin sensitivity and lower androgenic drive.
Read the study here
Endometriosis
Modulating the estrobolome and gut inflammation decreases estrogen recirculation and pelvic inflammatory signaling.
Read the study here
Mental Health Conditions
Major depression
Meta-analyses show compositional shifts and pathway changes in MDD; gut–brain axis mechanisms reviewed.
Read the study here
ME/Chronic Fatigue Syndrome
Multi-omics identify reduced butyrate-producing capacity and network disturbances tied to fatigue severity.
Read the study here
Migraine
Enrichment of nitrate-reducing bacteria associates with migraine phenotypes (hypothesized vascular mechanism)
Read the study here
Autism spectrum (select findings)
Microbial metabolites (e.g., 4-EPS) implicated in neurobehavior in translational work
Read the study here
Renal & Bone Conditions
Chronic kidney disease
Shifting away from proteolytic dysbiosis reduces uremic toxins (indoxyl sulfate, p-cresyl sulfate) that accelerate renal and vascular injury.
Read the study here
Osteoporosis/low BMD
SCFAs enhance mineral absorption and favor bone-forming immune signals while reducing resorptive inflammation.
Read the study here
Cancer
Colorectal cancer/adenomas
Balanced communities reduce genotoxins and increase butyrate-mediated epithelial protection and antitumor immune surveillance.
Read the study here
Post-Infectious/Long COVID
Long COVID
Reshaping the microbiome has been shown to improve glycemic control.
Read the study here